ClinicalTrials.gg
CompletedNCT00884260Updated Aug 21, 2014

GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China

A Phase 3 interventional study of Levonorgestrel IUS (LCS, BAY86-5028) in Contraception, sponsored by Bayer. Completed at 25 sites in 3 countries. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-21.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
918
Allocation
Non-randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The purpose of this study is to assess the efficacy, safety, bleeding pattern of low dose LNG (12 mg/ 24 hrs), delivered locally by a new intrauterine contraceptive system suitable for use by women 18 to 40 years of age. In addition, pharmacokinetic assessments will be performed.

02

Conditions studied

  • Contraception

Keywords

  • Contraception
  • Intrauterine contraception system
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has, in the opinion of the investigator, suitable general and uterine conditions for inserting the LCS.
  • Normal cervical smear (normal cervical smear within the last six months prior to visit 1 presented in writing can be accepted. The cervical smear should be analyzed and reported according to the Bethesda System.)
  • Has clinically normal safety laboratory results (i.e., inside the specified range for inclusion).
  • Has regular menstrual cycles (length of cycle 21-35 days) (i.e., endogenous cyclicity without hormonal use).

Exclusion criteria

Exclusion Criteria:

  • Known or suspected pregnancy or is lactating.
  • Vaginal delivery, cesarean delivery, or abortion within 6 weeks prior to visit 2.

Note: Postpartum insertions should be postponed until uterus is fully involuted, however not earlier than 6 weeks after delivery. If involution is substantially delayed, consider waiting until 12 weeks postpartum. In case of a difficult insertion and/or exceptional pain or bleeding during or after insertion, physical examination and ultrasound should be performed immediately to exclude perforation.

  • History of ectopic pregnancies. Note: For Korea only: History of ectopic pregnancies or high probability of ectopic gestation.
  • Infected abortion within 3 months prior to visit 1. Note: For Korea only: Endometritis after delivery or infected abortion within 3 months prior to visit 1.
  • Abnormal uterine bleeding of unknown origin.
  • Any genital infection (until successfully treated).
  • History of, or current, pelvic inflammatory disease
  • Congenital or acquired uterine anomaly.
  • Any distortion of the uterine cavity (by e.g., fibroids) likely to cause problems (in the opinion of the investigator) during insertion, retention or removal of the LCS.
  • History of, diagnosed or suspected genital , and untreated cervical dysplasia.
  • Current deep venous thrombosis or thrombophlebitis; history of deep venous thrombosis.
  • endometrial polyp(s), which, in the opinion of the investigator, will interfere with the assessment of the bleeding profile during the study
  • Clinically significant ovarian cyst(s)
  • Use of any long-acting injectable sex-hormone preparations within 12 months prior to start of study medication, and if entering subset: any sex-hormone administration within one month prior to start of the study medication.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
918 participants (actual)

Study arms

  • Experimental
    Arm 1

    Drug: Levonorgestrel IUS (LCS, BAY86-5028)

Interventions

  • DrugLevonorgestrel IUS (LCS, BAY86-5028)

    In Vitro release rate: 12µg LNG/24h

06

What researchers measure

Primary outcomes

  1. Primary efficacy variable is the occurrence of pregnancy, the Pearl Index (PI) is defined as the number of pregnancies per 100 woman years.

    Time frame: 3 years

Secondary outcomes

  1. LCS expulsion rate

    Time frame: 3 years

  2. Discontinuation rates

    Time frame: 3 years

  3. Adverse events

    Time frame: 3 years

  4. Laboratory tests

    Time frame: 3 years

07

Study locations

25 sites
  • Ashfield, New South Wales 2031, Australia
  • Herston, Queensland 4029, Australia
  • Parkville, Victoria 3052, Australia
  • Subiaco, Western Australia 6008, Australia
  • Guangzhou, Guangdong 510405, China
  • Wuhan, Hubei 430030, China
  • Nanjing, Jiangsu 210008, China
  • Nanjing, Jiangsu 210009, China
  • Nanjing, Jiangsu, China
  • Dalian, Liaoning 116011, China
  • Jinan, Shandong, China
  • Chengdu, Sichuan 610041, China
  • Beijing, 100034, China
  • Beijing, 100191, China
  • Beijing, 100730, China
  • Chongqing, 400010, China
  • Chongqing, 400042, China
  • Shanghai, 200011, China
  • Shanghai, 200025, China
  • Shanghai, 200127, China
  • Sungnam-si, Gyeonggido 463-712, Korea, Republic of
  • Seoul, Korea 100-380, Korea, Republic of
  • Seoul, 110-744, Korea, Republic of
  • Seoul, 120-752, Korea, Republic of
  • Seoul, 138-736, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2009
First posted
Apr 20, 2009
Start
Apr 2009
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Last update
Aug 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00884260
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Apr 20, 2009
Start date
Apr 2009
Primary completion
Jun 2013
Completion
Jun 2013
Last update
Aug 21, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion